4551.T Torii Pharmaceutical (JPX) JPY 6,350 pre-market 10 Feb 2026: bounce

4551.T stock trades at JPY 6,350.00 in the pre-market on 10 Feb 2026, setting up a clear oversold bounce opportunity for short-term traders. Volume is 48,100.00 shares and the intraday range is JPY 6,330.00–6,350.00, suggesting thin pre-market trade. Torii Pharmaceutical Co., Ltd. (JPX) shows a PE of 33.00 and EPS of 192.43, while balance-sheet ratios point to strong liquidity with a current ratio of 5.18. We outline a concise trade plan, valuation context, and Meyka AI forecast comparison for investors watching the rebound.

Technical setup for 4551.T stock

Price action in the pre-market places 4551.T stock at JPY 6,350.00, close to the Keltner middle band at JPY 6,350.00, and with an ATR of 20.00, indicating compressed volatility ahead of the open.

Short-term technicals show an oversold bounce pattern: intraday support near JPY 6,330.00 and immediate resistance at JPY 6,500.00. Traders can look for a confirmed break above JPY 6,420.00 on volume above 49,218.00 average to validate a bounce.

Fundamentals and valuation for 4551.T stock

Torii Pharmaceutical Co., Ltd. reports EPS 192.43 and a PE ratio of 33.00, with a price-to-book of 1.46, reflecting a premium to book but reasonable PB versus peers. Market capitalisation is JPY 178,531,513,650.00 and cash per share is JPY 1,203.19, supporting liquidity.

Profitability metrics include a net profit margin of 8.52% and ROE of 4.46%, while R&D sits at 5.42% of revenue, consistent with a specialty drug maker balancing margin and pipeline spend.

Sector context and catalysts for 4551.T stock

In Japan’s Healthcare sector, average PE is 24.12; 4551.T stock at 33.00 trades at a premium versus the sector, reflecting niche specialty products such as Riona, REMITCH, and CORECTIM.

Near-term catalysts include product uptake in dermatology and dialysis pruritus markets, and the next earnings window on 2025-07-29. Sector money flow remains modest; watch larger peers and industry news for spillover moves.

Meyka AI grade and valuation summary for 4551.T stock

Meyka AI rates 4551.T with a score out of 100: 72.80 (B+) — Suggestion: BUY. This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus.

The grade reflects strong liquidity (current ratio 5.18) and healthy cash per share JPY 1,203.19, offset by a higher PE. These inputs inform both our technical bounce view and longer-term valuation.

Trade plan and risk controls for 4551.T stock (oversold bounce)

For an oversold bounce trade, target an initial upside to JPY 6,700.00 with a tighter intraday target at JPY 6,500.00; place stop loss early at JPY 6,200.00 to limit downside. Size positions to risk no more than 1.0%–2.0% of portfolio on a single trade.

If price breaks below JPY 6,200.00 on volume above 49,218.00, re-evaluate the setup. Use a trailing stop if the bounce gains momentum toward mid-term resistance near JPY 7,000.00.

News, pipeline and calendar items affecting 4551.T stock

Torii’s product mix—Riona, REMITCH, ANTEBATE, CEDARCURE, MITICURE, and CORECTIM—creates event-driven price moves when uptake or regulatory updates occur; watch product-specific announcements and hospital formulary wins.

Key calendar items include the FY earnings announcement on 2025-07-29 and any regulatory updates from Japan’s health authorities. Sources: Torii Pharmaceutical official site and company profile pages on financial news platforms for updates.

Final Thoughts

Key takeaways: 4551.T stock trades at JPY 6,350.00 in the pre-market on 10 Feb 2026, presenting a short-term oversold bounce setup with low pre-market range and near-term support at JPY 6,330.00. Meyka AI’s forecast model projects a near-term yearly level of JPY 5,526.11, implying a -12.97% move versus the current price, and a three-year projection of JPY 6,581.12, implying +3.64% upside. Meyka AI’s forecast model projects further longer-term targets at JPY 7,634.08 (five years, +20.22%) and JPY 8,576.16 (seven years, +35.06%). Forecasts are model-based projections and not guarantees. For traders, use tight risk controls: initial targets JPY 6,500.00–6,700.00 and stop near JPY 6,200.00. For longer-term investors, fundamentals show liquidity and product diversification but a premium PE of 33.00, so position sizing should reflect valuation and sector backdrop. Meyka AI provides this as AI-powered market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.